IBM
International Business Machines Corporation
IBM's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over IBM overall, supported by stronger fundamentals and stronger modeled upside.
IBM Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Under pressure |
IBM's profitability and cash flow are currently strong, and its revenue is stable, but its balance sheet is under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
IBM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 17x | $194 | -21% |
| Forward | 19x | $245 | — |
| Current | 21x | $245 | — |
| Fair | 23x | $274 | +12% |
| Expensive | 46x | $538 | +120% |
Historical ranges are pointers, not guarantees.
IBM has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
IBM Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Stable | |
| Improving | |
| Moderate | |
| Moderate |
Analysts expect IBM's earnings to grow and its profitability to improve, with its revenue holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over IBM on the outlook, with more favorable revenue expectations.
IBM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.06 | +11% |
| Q3 2026 | $11.75 | +40% |
| Q2 2026 | $11.29 | +83% |
| Q1 2026 | $11.33 | +94% |
| Q4 2025 | $11.17 | +74% |
| Q3 2025 | $8.38 | +22% |
| Q2 2025 | $6.18 | -32% |
| Q1 2025 | $5.83 | -34% |
| Q4 2024 | $6.43 | -21% |
IBM earned $11.75 per share over the past year, up 40% from the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over IBM on earnings, with more consistent year-over-year improvement.
IBM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $17.1B | +4.7% |
| Q2 2026 | $17.2B | +1.1% |
| Q1 2026 | $15.9B | +9.5% |
| Q4 2025 | $19.7B | +12% |
| Q3 2025 | $16.3B | +9.1% |
| Q2 2025 | $17B | +7.7% |
| Q1 2025 | $14.5B | +0.5% |
| Q4 2024 | $17.6B | +1% |
IBM's revenue has grown year over year for 13 quarters in a row: $17.1B last quarter, up 4.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 15% | -0.3 points |
| Q2 2026 | 14% | -0.9 points |
| Q1 2026 | 8.7% | +0.8 points |
| Q4 2025 | 21% | +2.2 points |
| Q3 2025 | 15% | +20 points |
| Q2 2025 | 15% | +1.2 points |
| Q1 2025 | 8% | +0.5 points |
| Q4 2024 | 19% | -2.8 points |
IBM's operating margin was 15% last quarter, about level with the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over IBM on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over IBM on profitability, with a higher operating margin.
IBM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +31% |
| Q2 2026 | $2.4B | +59% |
| Q1 2026 | $4.9B | +20% |
| Q4 2025 | $3.7B | -9.2% |
| Q3 2025 | $2.8B | +8.9% |
| Q2 2025 | $1.5B | -19% |
| Q1 2025 | $4.1B | +5% |
| Q4 2024 | $4B | -3.3% |
IBM's free cash flow has been positive every quarter for seven years: $14.7B over the past year, up 18% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over IBM on cash flow, with more consistent year-over-year improvement.
IBM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +260K shares |
| 1 year | +0.5% | +4.6M shares |
| 3 years | +3.2% | +29.9M shares |
| 5 years | +5.3% | +47.6M shares |
| Available history | +2.1% | +19.6M shares |
IBM has 954M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over IBM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
IBM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.9x | Elevated |
| Q2 2026 | 3.9x | Elevated |
| Q1 2026 | 4.0x | High |
| Q4 2025 | 3.5x | Elevated |
| Q3 2025 | 4.2x | High |
| Q2 2025 | 5.5x | High |
| Q1 2025 | 5.6x | High |
| Q4 2024 | 4.4x | High |
IBM's net debt is about 3.9 years of its operating earnings (EBITDA), down from 4.2 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over IBM on leverage, with a lower net debt burden relative to earnings.
IBM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.1 | Neutral |
| Stochastic | 74.8 | Neutral |
IBM's weekly RSI is 50 (neutral) and its Stochastic is 75 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
IBM PE vs Technology Sector
| Metric | IBM | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 31 | 35 | 4 pts below |
IBM has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
IBM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $238.6 | 2.6% above |
| 20 week MA | $239.3 | 2.2% above |
| 50 week MA | $256.6 | 4.6% below |
| 100 week MA | $258.5 | 5.3% below |
| 200 week MA | $212.3 | 15% above |
IBM's trend is mixed: it's above three of its five weekly moving averages, and 15% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over IBM on trend strength, trading above more of its moving averages.
IBM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $129.3 | $119.2 | -7.8% |
| 2021 | $119.2 | $130.6 | +9.6% |
| 2022 | $130.6 | $141.7 | +8.4% |
| 2023 | $141.7 | $163.6 | +15% |
| 2024 | $163.6 | $222.8 | +36% |
| 2025 | $222.8 | $305.1 | +37% |
| 2026 YTD | $305.1 | $244.7 | -20% |
IBM has finished higher in five of the last six years. It's down 20% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over IBM on returns for 2026, with the stronger performance.